Imperial College London
Alternate

DrLucaMagnani

Faculty of Medicine, Department of Surgery & Cancer

Principal Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2808l.magnani CV

 
 
//

Location

 

140ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Magnani:2017:10.1038/ng.3773,
author = {Magnani, L and Frige, G and Gadaleta, RM and Corleone, G and Fabris, S and Kempe, MH and Vershure, PJ and Barozzi, I and Vircillo, V and Hong, S and Perone, Y and Saini, M and Trumpp, A and Viale, G and Neri, A and Simak, A and Colleoni, MA and Pruneri, G and Minucci, S},
doi = {10.1038/ng.3773},
journal = {Nature Genetics},
pages = {444--450},
title = {Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer},
url = {http://dx.doi.org/10.1038/ng.3773},
volume = {49},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα)  positive breast cancer (BCa) patients are  treated with adjuvant endocrine therapy2including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs)3. However, over 20% of patients relapse within 10  years and  eventually progress to  incurable metastatic disease4.  Here we  demonstratethat the  choice of  therapy has a fundamental influence on the genetic landscape of relapsed diseases: in this study, 21.5% of AI-treated, relapsed patients had  acquiredCYP19A1gene (aromatase) amplification (CYP19A1amp). Relapsed patients also developed numerous mutations targeting key  breast cancer genes including ESR1 and CYP19A1. Strikingly, CYP19A1amp cells also emerge in vitrobut  only in AI  resistant models. CYP19A1 amplification causesincreased aromatase activity and  estrogen-independent ERα binding to target genesresulting inCYP19A1amp cells displaying decreased sensitivity to  AI  treatment.  Collectively these data suggest that  AI  treatment itself selects for acquiredCYP19A1 amplification and promotes local autocrine estrogen signalling in AI resistant metastatic patients.
AU  - Magnani,L
AU  - Frige,G
AU  - Gadaleta,RM
AU  - Corleone,G
AU  - Fabris,S
AU  - Kempe,MH
AU  - Vershure,PJ
AU  - Barozzi,I
AU  - Vircillo,V
AU  - Hong,S
AU  - Perone,Y
AU  - Saini,M
AU  - Trumpp,A
AU  - Viale,G
AU  - Neri,A
AU  - Simak,A
AU  - Colleoni,MA
AU  - Pruneri,G
AU  - Minucci,S
DO  - 10.1038/ng.3773
EP  - 450
PY  - 2017///
SN  - 1546-1718
SP  - 444
TI  - Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
T2  - Nature Genetics
UR  - http://dx.doi.org/10.1038/ng.3773
UR  - http://hdl.handle.net/10044/1/43545
VL  - 49
ER  -
Download